NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Total Assets
NeuBase Therapeutics Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Total Assets
$18.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$133.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Total Assets?
Total Assets
18.6m
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Total Assets amounts to 18.6m USD.
What is NeuBase Therapeutics Inc's Total Assets growth rate?
Total Assets CAGR 10Y
12%
Over the last year, the Total Assets growth was -43%. The average annual Total Assets growth rates for NeuBase Therapeutics Inc have been -19% over the past three years , 10% over the past five years , and 12% over the past ten years .
